Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$56.41
52-Week Range
Decision Context
Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — BMY
Inflationary BoomStrengths
Net Income: $7.1B (+178.8% YoY) — Profit grew 179% — the company kept more of each dollar earned.
EPS (Diluted): $3.46 (+178.5% YoY) — Earnings per share rose 178% — each share earned more.
Gross Profit: $30.7B (+70.2% YoY) — Gross profit rose 70% — the spread between revenue and direct costs improved.
Weaknesses
Operating Cash Flow: $14.2B (-6.8% YoY) — Operating cash flow fell 7% but remained positive.
Total Assets: $90.0B (-2.8% YoY) — Total assets shrank 3% — the balance sheet contracted.
Opportunities
No clear opportunities identified at this time.
Threats
Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Net Income
$7.1B
was -$8.9B
Profit grew 179% — the company kept more of each dollar earned.
EPS (Diluted)
$3.46
was $-4.41
Earnings per share rose 178% — each share earned more.
Gross Profit
$30.7B
was $18.1B
Gross profit rose 70% — the spread between revenue and direct costs improved.
Operating Cash Flow
$14.2B
was $15.2B
Operating cash flow fell 7% but remained positive.
Total Assets
$90.0B
was $92.6B
Total assets shrank 3% — the balance sheet contracted.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — BMY
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade BMY
Links open broker research pages. Not an endorsement or recommendation.
Research Bristol-Myers Squibb Company
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.